Patents by Inventor Lourdes Ponce

Lourdes Ponce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
    Patent number: 8039585
    Abstract: Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: October 18, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Karl G. Csaky, Hynda Kleinman, Lourdes Ponce
  • Therapeutic Administration Of The Scrambled Anti-Angiogenic Peptide C16Y
    Publication number: 20080131430
    Abstract: Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
    Type: Application
    Filed: February 12, 2004
    Publication date: June 5, 2008
    Inventors: Karl G. Csaky, Hynda Kleinman, Lourdes Ponce